Compare CRSP & ESNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRSP | ESNT |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | Switzerland | Bermuda |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 5.9B |
| IPO Year | 2016 | 2013 |
| Metric | CRSP | ESNT |
|---|---|---|
| Price | $50.24 | $64.38 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 7 |
| Target Price | ★ $71.95 | $68.71 |
| AVG Volume (30 Days) | ★ 1.8M | 741.0K |
| Earning Date | 02-11-2026 | 02-13-2026 |
| Dividend Yield | N/A | ★ 1.97% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 6.87 |
| Revenue | $38,337,000.00 | ★ $1,263,558,000.00 |
| Revenue This Year | N/A | $3.55 |
| Revenue Next Year | $1,376.73 | $0.85 |
| P/E Ratio | ★ N/A | $9.17 |
| Revenue Growth | N/A | ★ 2.04 |
| 52 Week Low | $30.04 | $51.61 |
| 52 Week High | $78.48 | $67.09 |
| Indicator | CRSP | ESNT |
|---|---|---|
| Relative Strength Index (RSI) | 40.76 | 56.54 |
| Support Level | $49.10 | $60.92 |
| Resistance Level | $53.00 | $63.80 |
| Average True Range (ATR) | 3.12 | 1.33 |
| MACD | -0.48 | 0.30 |
| Stochastic Oscillator | 12.40 | 85.14 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Essent Group Ltd serves the housing finance industry by providing private mortgage insurance, reinsurance, risk management products, title insurance, and settlement services to mortgage lenders, borrowers, and investors to support homeownership. It provides credit protection to lenders and mortgage investors by covering a portion of the unpaid principal balance of a mortgage and certain related expenses in the event of a default. By providing capital to mitigate mortgage credit risk, the company allows lenders to make additional mortgage financing available to prospective homeowners.